Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048050 | 0.91 | IDO1 (0.54) | IDO1NPC1HPGDRAB9AGAA | |
| SCHEMBL134086 | 0.89 | IDO1 (0.61) | IDO1APPMAOBCHRM3TAAR1 | |
| SCHEMBL8418497 | 0.87 | IDO1 (0.50) | IDO1APPMAOBPOLBLMNA | |
| SCHEMBL9342149 | 0.86 | IDO1 (0.58) | IDO1APPMAOBCHRM3TAAR1 | |
| SCHEMBL21578433 | 0.86 | IDO1 (0.58) | IDO1APPMAOBCHRM3TAAR1 | |
| SCHEMBL9342899 | 0.86 | IDO1 (0.58) | IDO1APPMAOBCHRM3TAAR1 | |
| SCHEMBL1372413 | 0.85 | IDO1 (0.48) | IDO1NPC1HPGDRAB9AGAA | |
| SCHEMBL509255 | 0.83 | IDO1 (0.47) | IDO1NPC1HPGDRAB9AAPP | |
| SCHEMBL3106528 | 0.83 | IDO1 (0.50) | IDO1NPC1RAB9AGAAAPP | |
| SCHEMBL11108664 | 0.83 | TAAR1 (0.47) | IDO1NPC1HPGDRAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20230131260-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-9065062-B2 | Cross-linkable iridium complexes and organic light-emitting devices using the same | UNIVERSAL DISPLAY CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-9065062-B2 | Cross-linkable iridium complexes and organic light-emitting devices using the same | UNIVERSAL DISPLAY CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-20120107989-A1 | CROSS-LINKABLE IRIDIUM COMPLEXES AND ORGANIC LIGHT-EMITTING DEVICES USING THE SAME | UNIVERSAL DISPLAY CORPORATION | 2012-05-03 | — | — | US | disclosed |
| US-20120107989-A1 | CROSS-LINKABLE IRIDIUM COMPLEXES AND ORGANIC LIGHT-EMITTING DEVICES USING THE SAME | UNIVERSAL DISPLAY CORPORATION | 2012-05-03 | — | — | US | disclosed |
| US-8119255-B2 | First and second electrode; a first organic layer between the electrodes; the first organic layer is a non-electroluminescent, cross-linked metal complex; and a second organic layer is an emissive electroluminescent organic material | UNIVERSAL DISPLAY CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119255-B2 | First and second electrode; a first organic layer between the electrodes; the first organic layer is a non-electroluminescent, cross-linked metal complex; and a second organic layer is an emissive electroluminescent organic material | UNIVERSAL DISPLAY CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20080220265-A1 | Cross-linkable Iridium Complexes and Organic Light-Emitting Devices Using the Same | UNIVERSAL DISPLAY CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080220265-A1 | Cross-linkable Iridium Complexes and Organic Light-Emitting Devices Using the Same | UNIVERSAL DISPLAY CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008073440-A2 | CROSS-LINKABLE IRIDIUM COMPLEXES AND ORGANIC LIGHT-EMITTING DEVICES USING THE SAME | UNIVERSAL DISPLAY CORPORATION (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1140896-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6235771-B1 | AIDS THERPAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| WO-2000037455-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080220265-A1 | Cross-linkable Iridium Complexes and Organic Light-Emitting Devices Using the Same | MTCL3, LIG4, L1CAM | IDO1 227/4885NPC1 4795/4885HPGD 2118/4885 |
| US-20120107989-A1 | CROSS-LINKABLE IRIDIUM COMPLEXES AND ORGANIC LIGHT-EMITTING DEVICES USING THE SAME | MTCL3, LIG4, L1CAM | IDO1 227/4885NPC1 4795/4885HPGD 2118/4885 |
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | PFAS, DDT, NOTUM | IDO1 860/4885NPC1 4691/4885HPGD 272/4885 |
| US-20230131260-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | UNG, TYMP, TYMS | IDO1 552/4885NPC1 4836/4885HPGD 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.